Drugs / FT836
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07216105 | Nov 2025 → Jan 2028 expected | breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma +2 | Fate Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216105 ↗ |
| Modality | Cell therapy | “FT836, an Off-the-Shelf CAR T-Cell Therapy” NCT07216105 ↗ |
| Route | Intravenous | “FT836 drug product is administered as an intravenous infusion” NCT07216105 ↗ |